Search
-
Affluent African American consumers in context: Buying while black
Ipsos shares data through a new lens, to illustrate how a pervasive climate of racism impacts the behaviour of African Americans.
-
Moving beyond the start: How to maintain changed behaviours
Governments around the world are currently introducing measures to reduce the spread of COVID-19; these include closing schools and universities, cancelling events, restricting access to care homes and encouraging home working. More extreme measures can include quarantine for whole areas, requiring people to stay in their homes and not travel. The article was published on Research World.
-
Ipsos Update - June 2020
This month’s round-up of research and analysis from Ipsos around the world includes the latest insights on the impacts of coronavirus and how we can plan for the future, customer experience – including the emerging health and safety agenda, attitudes to work, the second world war, and public opinion from New Zealand and Australia.
-
Evaluating and adapting your soon-to-launch pharma strategy
Covid-19 has greatly disrupted the channels of communication between healthcare professionals and pharma manufacturers, especially those preparing for a product launch.
-
London ranks as the top “City Brand.” Sydney emerges in second place, while Paris declines from first in 2017 to third in 2020
London is the world’s top “City Brand”, with Sydney, Paris, New York, and Rome rounding out the top five, according to the people in ten countries surveyed for the Anholt-Ipsos City Brands Index.
-
The new definition of luxury
Read Oscar Yuan's take on the new definition of Luxury in Bloomberg's piece: Ultra-Luxury Hotelier Aman Launches a New, More-Affordable Brand.
-
The power of Payer insights tracking in times of turbulence and market disruption [Webinar recording]
Watch our on-demand webinar to explore the biggest future Payer challenges and look at how traditional ATUs can be complemented by a more dynamic approach to tracking, one which encompasses Payers in addition to HCPs and therapy monitoring.